News and Events
- Irish Cement Industrial Visit
- Stage 2 and 3 lunch gatherings
- First EDI Coffee morning of 2024-25
- Sinead Kerins retires
- MacElroy Energy Bursary 2024
- Annual SCBE Seminar Day 2024
- SCBE Student wins Naughton Fellowship
- 2023 News Archive
- 2022 News Archive
- 2020 News Archive
- 2019 News Archive
- 2018 News Archive
- 2017 News Archive
- 2016 News Archive
- Celebrating 60 Years of UCD Chemical & Bioprocess Engineering
- PSE Model-Based Innovation Prize 2016
- UCD Spin-Out Company, APC, named Irish Pharma Company of the Year
- Student Awards 2016
- IChemE All-Ireland Sports Day 2016
- European Biotech SME award
- UCD EGA Distinguished Graduate Award
- U21 Summer School 2016
- Congratulations to Chem and Bioprocess Engineering Class of 2016
- Oxymem Founders win NovaUCD Innovation Award
- KTI 2015
- Dow invests in OxyMem’s wastewater treatment technology
- APC Ltd Announces 100 Jobs and Opens New Research Facility in Dublin
- U21 Undergraduate Research Conference: People and Places
- Eli Lilly IChemE Sponsorship
APC Ltd Announces 100 Jobs and Opens New Research Facility in Dublin
Thursday, 19 May, 2016
Professor Brian Glennon, co-founder, APC, An Taoiseach Enda Kenny TD and Dr Mark Barrett, co-founder, APC
The announcement was made as An Taoiseach Enda Kenny TD officially opened the company’s new world-class, state-of-the-art process research facility in Cherrywood, Dublin. The new 6,000m² premises will also serve as the company’s new headquarters.
APC is an innovator in process research solutions for the drugs industry and helps global clients accelerate the development of their medicines for a wide range of conditions including cancer and HIV. The company’s move to Cherrywood Business Park is part of APC’s rapid expansion as it looks to more than double its workforce to meet client demand.
The company was established by Professor Brian Glennon and Dr Mark Barrett in 2011 as a spin-out from the UCD School of Chemical and Bioprocess Engineering. The company won the NovaUCD 2011 Start-up of the Year Award after being declared overall winner of the 16th NovaUCD Campus Company Development Programme, the forerunner of the current UCD VentureLaunch Accelerator Programme.
In the space of just 4 years, the company, supported by Enterprise Ireland, has pioneered innovation in the pharmaceutical sector and now partners with 8 of the top 10 pharma and 5 of the top 10 biotech firms in the world. 80% of its services are export-driven and the company aims to reach revenues of €50 million by 2020.
Speaking at the launch, the Taoiseach said, “I am delighted to welcome the announcement by APC of 100 new jobs in Dublin. This new research centre is a vote of confidence in Ireland and enhances our reputation as a leading location for pharmaceutical research and development. It is also a shining example of how a thriving business can grow from a bright idea once the right conditions are created by the right Government policies. The Government wants to keep the recovery going so that companies like APC can continue to grow and create jobs.”
Minister for Jobs, Enterprise and Innovation Richard Bruton said, “The 100 jobs announced by APC Ltd is another vote of confidence for our pharma med tech sector. As part of our Action Plan for Jobs we have put in place a range of measures specifically aimed at attracting research and development activity to Ireland. Today’s announcement that APC Ltd, a world leader in pharmaceutical research, is expanding in Ireland and creating 100 jobs is very welcome. I wish Mark and the APC team the very best for their future as they continue to grow their business.”
Dr Mark Barrett, APC CEO, said, “Our success has come from working with talented and creative engineers and scientists. We are looking to expand the team with today's announcement of 100 highly-skilled research and development jobs across chemical engineering, sciences and analytics. We need people who enjoy the rewards of working in an environment that is driven by cutting-edge technology and science. In return, we will provide them with an opportunity to do something extraordinary: to help change patient outcomes for the better.”